Cost-Effectiveness Analysis of Antihypertensive Combination Therapy among Patients with Moderate to Severe Hypertension

Abstract

Objectives: The model objective is to estimate and compare the cost consequences to hospitals, using two different active flowable hemostatic matrices (i.e. Floseal and Surgiflo) in cardiac surgery. MethOds: Using clinical outcomes from a published retrospective (US Premier Hospital Database) comparative effectiveness analysis of two hemostatic matrices in cardiac surgery patients[1], a cost-consequence framework was utilized to model the economic impact to hospitals of their use. The average annual number of cardiac surgeries and costing of major and minor complications, blood transfusions, and surgical revisions was analyzed using the 2012 Healthcare Cost and Utilization Project's (HCUP's) National Inpatient Sample (NIS) database (represents 95% of all U.S. community hospital discharges). Cost of hemostatic matrices and operating room (OR) was obtained from RED BOOK™ and published literature. All costs were adjusted to 2015 dollars using medical care consumer price index (CPI-medical care). One-way (OWSA) and probabilistic sensitivity analyses were performed by varying all variables within the 95% confidence interval (CI) of the point estimate or ±20% when CI was not available. [1]